A Multi-center, Randomized, Blinded, Placebo-controlled, Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021) as Booster in Participants Aged 18 Years and Older who Completed Primary/1 Booster Dose(s) of SARS-CoV-2 Vaccination
Study Status: Recruitment Completed
Thanks to All the Participants and their families for the active participation in the Trial
RMI is elated to share that Zara Anjum, our dedicated Clinical Research Associate of the Clinical Trials Unit (CTU), has achieved an outstanding feat by
AIMS Biosciences Project Manager Visits RMI CTU Chen Xhin Hui, Project Manager of Aims Biosciences, visited RMI’s Clinical Trials Unit (CTU) for monitoring, quality control,
A Multi-center, Randomized, Blinded, Placebo-controlled, Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021) as Booster in
A Phase 3, multicenter, randomized, double-blind, 48-week study of the clinical and antiviral effect of S 217622 compared with placebo in non-hospitalized high risk participants
Trial Name Disease Area CML Oncology Breast cancer Oncology CABG Cardiology Fungal infection evaluation Infectious Diseases Alzheimer’s Disease Neurology Alkylosing Spondyloarthritis Rheumatology Advanced Melanoma Oncology
